Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure

Summary

Endothelial dysfunction and enhanced platelet reactivity in congestive heart failure (CHF) contribute to poor prognosis. CHF patients display an impaired responsiveness to clopidogrel. Fractalkine activates platelets and elevated plasma levels of this chemokine are a feature of CHF. We here addressed the interrelation of fractalkine, platelet reactivity and clopidogrel efficacy in humans and rats with CHF. Fractalkine serum levels determined by ELISA were increased in CHF patients (CHF: 1548 ± 650 pg/ml; Control: 968 ± 575 pg/ml, p<0.01) and following CHF induction in rats (CHF: 1509 ± 753 pg/ ml; Sham: 1181 ± 275 pg/ml, p<0.05). Expression of fractalkine and its receptor CX₃CR1 was enhanced in aortas of CHF rats as determined by immunofluorescence microscopy and molecular analysis. Fractalkine significantly aggravated endothelial dysfunction and augmented P-selectin expression on platelets from CHF rats. Platelet surface expression of CX₃CR1 was increased in CHF rats, who displayed an impaired response to clopidogrel (platelet reactivity to ADP: CHF 30 ± 22%; Sham: 8 ± 5%, p<0.05). Similarly in humans with CHF, elevated fractalkine levels were accompanied by reduced clopidogrel responsiveness. Patients with high on-clopidogrel treatment platelet P2Y₁₂ reactivity displayed higher fractalkine levels (1525 ± 487 pg/ml) than those with sufficient clopidogrel response (684 ± 315 pg/ml, p<0.01). In conclusion, in CHF fractalkine was increased on the endothelium and in blood serum, and platelet surface- expression of CX₃CR1 was enhanced. Fractalkine diminished endothelial function beyond the impairment already observed in CHF and was associated with a reduced responsiveness to the platelet inhibitor clopidogrel. These findings may indicate a novel pathophysiological mechanism contributing to impaired clopidogrel responsiveness in CHF.

Keywords

Fractalkine - chemokines - heart failure - platelets - endothelial dysfunction - clopidogrel

• References

• 1 Gibbs CR, Blann AD, Watson RD. et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm : Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.. Circulation 2001; 103: 1746-1751.
• 2 Schäfer A, Fraccarollo D, Hildemann S. et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition: Role of endothelial function and platelet VASP phosphorylation.. Thromb Haemost 2003; 89: 1024-1030.
• 3 Loh E, St John Sutton M, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction.. N Engl J Med 1997; 336: 251-257.
• 4 Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside.. Circulation 1979; 60: 497-503.
• 5 Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis.. Circ Res 2001; 88: 756-762.
• 6 Schäfer A, Alp NJ, Cai S. et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo.. Arterioscler Thromb Vasc Biol 2004; 24: 1720-1726.
• 7 Schäfer A, Wiesmann F, Neubauer S. et al. Rapid regulation of platelet activation in vivo by nitric oxide.. Circulation 2004; 109: 1819-1822.
• 8 Schäfer A, Fraccarollo D, Eigenthaler M. et al. Rosuvastatin reduces platelet activation in heart failure: role of nitric oxide bioavailability.. Arterioscler Thromb Vasc Biol 2005; 25: 1071-1077.
• 9 Weber C. Platelets and chemokines in atherosclerosis: partners in crime.. Circ Res 2005; 96: 612-616.
• 10 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease.. N Engl J Med 2005; 352: 1685-1695.
• 11 Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease.. Circ Res 2004; 95: 858-866.
• 12 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation.. N Engl J Med 2006; 354: 610-621.
• 13 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound che-mokine with a CX3C motif.. Nature 1997; 385: 640-644.
• 14 Harrison JK, Jiang Y, Wees EA. et al. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart.. J Leukoc Biol 1999; 66: 937-944.
• 15 Damas JK, Gullestad L, Ueland T. et al. CXC-chemokines, a new group of cyto-kines in congestive heart failure-- possible role of platelets and monocytes.. Car- diovasc Res 2000; 45: 428-436.
• 16 Stolla M, Pelisek J, von Brühl M-L. et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1.. PLoS ONE 2012; 7: e43572.
• 17 Damas JK, Boullier A, Waehre T. et al. Experession of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.. Arterioscler Thromb Vasc Biol 2005; 25: 2567-2572.
• 18 Richter B, Koller L, Hohensinner PJ. et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure.. Thromb Haemost 2012; 108: 1220-1227.
• 19 Schäfer A, Schulz C, Fraccarollo D. et al. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions.. Arterioscler Thromb Vasc Biol 2007; 27: 55-62.
• 20 Umehara H, Bloom E, Okazaki T. et al. Fractalkine and vascular injury.. Trends Immunol 2001; 22: 602-607.
• 21 Greaves DR, Hakkinen T, Lucas AD. et al. Linked chromosome 16q13 chemo-kines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions.. Arterioscler Thromb Vasc Biol 2001; 21: 923-929.
• 22 Schäfer A, Schulz C, Eigenthaler M. et al. Novel role of the membrane bound chemokine fractalkine in platelet activation and adhesion.. Blood 2004; 103: 407-412.
• 23 Meyer dos SS, Klinkhardt U, Scholich K. et al. The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib.. Blood 2011; 117: 4999-5008.
• 24 Schulz C, Schäfer A, Stolla M. et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood, a critical role for P-selectin expressed on activated platelets.. Circulation 2007; 116: 764-773.
• 25 Gachet C. Regulation of platelet functions by P2 receptors.. Annu Rev Pharmacol Toxicol 2006; 46: 277-300.
• 26 Geiger J, Brich J, Honig-Liedl P. et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopido-grel.. Arterioscler Thromb Vasc Biol 1999; 19: 2007-2011.
• 27 Flierl U, Fraccarollo D, Lausenmeyer E. et al. Fractakine activates a signal trans-duction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.. Arterioscler Thromb Vasc Biol 2012; 32: 1832-1840.
• 28 Jin J, Kunapuli S. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
• 29 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.. Circulation 2003; 107: 2908-2913.
• 30 Schäfer A, Weinberger S, Flierl U. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.. Thromb Haemost 2008; 100: 618-625.
• 31 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.. J Am Coll Cardiol 2005; 46: 1827-1832.
• 32 Wenaweser P, Dorffler-Melly J, Imboden K. et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy.. J Am Coll Cardiol 2005; 45: 1748-1752.
• 33 Glowczynska R, Malek LA, Spiewak M. et al. Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis—a case report and review of the literature.. Int J Cardiol 2006; 111: 326-328.
• 34 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.. Eur Heart J 2006; 27: 2420-2425.
• 35 Geisler T, Grass D, Bigalke B. et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score.. J Thromb Haemost 2008; 6: 54-61.
• 36 Smit JJ, ’t Hof AW, de Boer MJ. et al. Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction.. Thromb Haemost 2006; 96: 190-195.
• 37 Osmancik P, Jirmar R, Hulikova K. et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.. Catheter Cardiovasc Interv 2010; 75: 158-166.
• 38 Husberg C, Nygard S, Finsen AV. et al. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure.. J Mol Cell Cardiol 2008; 45: 261-269.
• 39 Fraccarollo D, Hu K, Galuppo P. et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilatation and improves cardiac function in rats with myocardial infarction. Possible involvement of myocardial endothelin system in ventricular remodeling.. Circulation 1997; 96: 3963-3973.
• 40 Bauersachs J, Galuppo P, Fraccarollo D. et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction.. Circulation 2001; 104: 982-985.
• 41 Wong BW, Wong D, McManus BM. Characterisation of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease.. Cardiovasc Pathol 2002; 11: 332-338.
• 42 Schäfer A, Fraccarollo D, Widder J. et al. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial NO synthase transcription enhancer.. Eur J Heart Fail 2009; 11: 336-341.
• 43 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting.. Thromb Haemost 2004; 92: 1201-1206.
• 44 Schäfer A, Fraccarollo D, Hildemann S. et al. Addition of the selective aldoste-rone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial function.. Cardiovasc Res 2003; 58: 655-662.
• 45 Blindt R, Stellbrink K, de Taeye A. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.. Thromb Hae-most 2007; 98: 1329-1334.
• 46 Bonello L, Paganelli F, Arpin-Bornet M. et al. Vasodilator-stimulated phospho-protein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.. J Thromb Haemost 2007; 5: 1630-1636.
• 47 Nahrendorf M, Swirski FK, Aikawa E. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions.. J Exp Med 2007; 204: 3037-3047.
• 48 Bauersachs J, Schäfer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches.. Curr Vasc Pharmacol 2004; 2: 115-124.
• 49 Dreymueller D, Martin C, Kogel T. et al. Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide.. EMBO Mol Med 2012; 4: 412-423.
• 50 Ludwig A, Berkhout T, Moores K. et al. Fractalkine is expressed by smooth muscle cells in response to IFN- gamma and TNF-alpha and is modulated by metalloproteinase activity.. J Immunol 2002; 168: 604-612.
• 51 Chirkov YY, Holmes AS, Willoughby SR. et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets.. J Am Coll Cardiol 2001; 37: 1851-1857.
• 52 Chirkov YY, Chirkova LP, Sage RE. et al. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.. J Cardiovasc Pharmacol 1995; 25: 961-966.
• 53 Willoughby SR, Stewart S, Holmes AS. et al. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes.. Arterioscler Thromb Vasc Biol 2005; 25: 2661-2666.
• 54 Anderson RA, Ellis GR, Chirkov YY. et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure.. Eur J Heart Fail 2004; 6: 47-54.
• 55 Cardona AE, Sasse ME, Liu L. et al. Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues.. Blood 2008; 112: 256-263.
• 56 Postea O, Vasina EM, Cauwenberghs S. et al. Contribution of platelet CX(3)CR1 to platelet-monocyte complex formation and vascular recruitment during hy-perlipidemia.. Arterioscler Thromb Vasc Biol 2012; 32: 1186-1193.
• 57 Flierl U, Schäfer A. Fractalkine - a local inflammatory marker aggravating platelet activation at the vulnerable plaque.. Thromb Haemost 2012; 108: 457-463.